Literature DB >> 22040566

Comparative study on the stem cell phenotypes of C6 cells under different culture conditions.

Suo-Jun Zhang1, Fei Ye, Rui-Fan Xie, Feng Hu, Bao-Feng Wang, Feng Wan, Dong-Sheng Guo, Ting Lei.   

Abstract

BACKGROUND: Glioma stem cell (GSC) hypothesis posits that a subpopulation of cells within gliomas have true clonogenic and tumorigenic potential. Significantly, a more controversial correlate to GSC is that cells in different culture conditions might display distinct stem cell properties. Considering these possibilities, we applied an approach comparing stem cell characteristics of C6 glioma cells under different culture conditions.
METHODS: C6 cells were cultured under three different growth conditions, i.e., adherent growth in conventional 10% serum medium, non-adherent spheres growth in serum-free medium, as well as adherent growth on laminin-coated flask in serum-free medium. Growth characteristics were detected contrastively through neurosphere formation assay and cell cycle analysis. Markers were determined by immunofluorescence, relative-quantitative reverse transcription (RT)-PCR, Western blotting and flow cytometry. Side population cells were analyzed via flow cytometry. Tumor models were detected by magnetic resonance imaging and hematoxylin & eosin staining. Data analyses were performed with SPSS software (17.0).
RESULTS: C6 cells (C6-Adh, C6-SC-Sph and C6-SC-Adh) showed distinctive growth patterns and proliferation capacity. Compared to suspending C6-SC-Sph, adherent C6-Adh and C6-SC-Adh displayed higher growth ratio. C6-SC-Sph and C6-SC-Adh showed enhanced capability of neurosphere formation and self-renewal. High side population ratio was detected in C6-SC-Sph and C6-SC-Adh. CD133 was not detected in all three kinds of cells. Conversely, Nestin and β-III-tubulin were demonstrated positive, nonetheless with no statistical significance (P > 0.05). Interestingly, lower expression of glial fibrillary acidic protein was demonstrated in C6-SC-Sph and C6-SC-Adh. C6-Adh, C6-SC-Sph and C6-SC-Adh were all displayed in situ oncogenicity, while statistical difference of survival time was not confirmed.
CONCLUSIONS: C6 glioma cell line is endowed with some GSC phenotypes that can be moderately enriched in vitro when transferred into stem cell culture condition. The resultant tumor-spheres may be not a prerequisite or sound source of GSCs and adherent culture in stem cell medium is not a growth condition in favor of GSCs expanding in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22040566

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  5 in total

1.  Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation.

Authors:  Elena Biasibetti; Alberto Valazza; Maria T Capucchio; Laura Annovazzi; Luigi Battaglia; Daniela Chirio; Marina Gallarate; Marta Mellai; Elisabetta Muntoni; Elena Peira; Chiara Riganti; Davide Schiffer; Pierpaolo Panciani; Michele Lanotte
Journal:  Comp Med       Date:  2017-03-01       Impact factor: 0.982

2.  The stemness phenotype model.

Authors:  M H Cruz; A Sidén; G M Calaf; Z M Delwar; J S Yakisich
Journal:  ISRN Oncol       Date:  2012-08-08

3.  Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines.

Authors:  Taghreed N Almanaa; Michael E Geusz; Roudabeh J Jamasbi
Journal:  BMC Complement Altern Med       Date:  2012-10-24       Impact factor: 3.659

4.  Identification of U251 glioma stem cells and their heterogeneous stem-like phenotypes.

Authors:  Suojun Zhang; Ruifan Xie; Feng Wan; Fei Ye; Dongsheng Guo; Ting Lei
Journal:  Oncol Lett       Date:  2013-10-11       Impact factor: 2.967

5.  Sacsin Deletion Induces Aggregation of Glial Intermediate Filaments.

Authors:  Fernanda Murtinheira; Mafalda Migueis; Ricardo Letra-Vilela; Mickael Diallo; Andrea Quezada; Cláudia A Valente; Abel Oliva; Carmen Rodriguez; Vanesa Martin; Federico Herrera
Journal:  Cells       Date:  2022-01-16       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.